• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Research and development > Portfolio

Pandemic Preparedness 

ASAP-0017445 (Moonshot ASAP)

objective

Develop a safe, affordable, and globally accessible, broad-spectrum antiviral targeting future corona virus pandemics 

project start
2024

current phase of drug development

Discovery project phase
Drug Discovery
Translation project phase
Translational research
clinical trials icon
Clinical trials
Treatment Access
Registration & access

updated 21 Feb 2025

There is fundamental lack of potent broad-spectrum antivirals ready to be deployed when the next pandemic hits. Together with partners in the AI-driven Structure-enabled Antiviral Platform (ASAP), AViDD Center, funded by the NIH, DNDi is working to progress the development of back-up compounds to the frontrunner SARS-CoV-2 main protease (Mpro) inhibitor named DNDI-6510, initially identified by the Covid Moonshot initiative.

The optimization work led by ASAP has successfully resulted in the design and synthesis of non-covalent broad spectrum coronavirus inhibitors of the MERS and SARS-CoV Mpro with further optimized potency and pharmacokinetic properties, demonstrated in vivo efficacy in pre-clinical models of SARS-CoV-2 and MERS-CoV infections. The leading compound, ASAP-0017445, is currently being progressed through off-target panel screening and extended toxicology studies with the aim to nominate a pre-clinical candidate.

News & resources

  • 31 March 2025 – A new pan-coronavirus protease inhibitor possibility, Science
  • 26 March 2025 – Antiviral unveiled that goes after multiple coronaviruses, C&EN
  • 15 July 2024 – Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements, Wellcome Open Research

Additional information

  • ASAP website
  • Members of the ASAP project
  • ASAP policy on intellectual property management and open science disclosure

Partners

  • Diamond Light Source, UK
  • Icahn School of Medicine at Mount Sinai, USA
  • MedChemica Ltd., UK
  • Memorial Sloan Kettering Cancer Center, USA
  • PostEra, UK/USA
  • Stanford University School of Medicine, USA
  • Weizmann Institute of Science, Israel
Loading…
  • Diamond Light Source
  • ,UK
  • Icahn School of Medicine at Mount Sinai
  • ,USA
  • MedChemica Ltd.
  • ,UK
  • Memorial Sloan Kettering Cancer Center
  • ,USA
  • PostEra
  • ,UK/USA
  • Stanford University School of Medicine
  • ,USA
  • Weizmann Institute of Science
  • ,Israel
  • PostEra, UK/USA
  • Memorial Sloan Kettering Cancer Center, USA
  • Diamond Light Source, UK
  • Weizmann Institute of Science, Israel
  • MedChemica Ltd., UK
  • Stanford University School of Medicine, USA
  • Icahn School of Medicine at Mount Sinai, USA

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License